Diagnostic Utility of Preferentially Expressed Antigen in Melanoma Immunohistochemistry in the Evaluation of Melanomas with a Co-Existent Nevoid Melanocytic Population: A Single-Center Retrospective Cohort Study

This study evaluated the use of PRAME immunohistochemistry as a diagnostic tool for distinguishing between benign and malignant melanocytic neoplasms, specifically in nevus-associated melanomas (NAMs). The study involved 36 NAMs, with PRAME expression assessed in both melanoma and nevus components. Results showed that PRAME was able to differentiate between benign and malignant melanocytic populations in 89% of cases, with high expression in melanoma cells and absent or minimal expression in nevus cells. The findings supported the utility of PRAME as an adjunct diagnostic tool, aiding in the accurate delineation of Breslow thickness and improving prognostication and management of these lesions.